After treading water for much of 2020, ZOM stock is up 786% in 2021. Quicker, more precise tests mean they can make treatment decisions faster than they traditionally could. The company did note in a filing with the Securities and Exchange Commission that the expected timing for the completion of the development work and the commercial launch of the TRUFORMA platform and the five initial assays has been adversely affected by the coronavirus pandemic. By clicking Accept All, you consent to the use of ALL the cookies. About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Readers are cautioned not to place undue reliance on forward-looking information. THIS IS SIGNIFICANT and could result in a very quick ROI for the vet offices. Copy and paste multiple symbols separated by spaces. However, theres no crystal ball to tell if it will be a hit with operators in the point-of-care diagnostics for cats and dogs. Reader AdvisoryExcept for statements of historical fact, this news release contains certain "forward-looking information" or forward-looking statements (collectively, forward-looking information) within the meaning of applicable securities law. https://www.youtube.com/embed/HDDbf76Ngt4, Do Not Sell My Personal Data/Privacy Policy. Zomedica noted that if the same samples are tested on two different types of machines and achieve exactly the same results, the correlation would be R=1. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. Zomedica is in the process of building its sales organization in preparation for commercial launch. Zomedica is expected to complete validation studies for TRUFORMA during the fourth quarter of 2019 with a planned commercial launch before the close of first quarter of 2020. And because buyer behavior dictates so much of what happens with a stock, Chris always keeps the end consumer close in mind. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. 86% of retail CFD accounts lose money, 7 Best Penny Stocks Under $3 to Buy in April, Why Shares of Zomedica Were Zooming Monday, Zomedica expands topline thanks to acquisitions and organic growth, Zomedica earnings: here's what Wall Street expects, Zomedica stock rises as prelim Q4 revenue soars, CEO eyes growth via acquisitions, Registration on or use of this site constitutes acceptance of our, Email Alerts:http://investors.zomedica.com, LinkedIn:https://www.linkedin.com/company/zomedica. Fill out the form below and one of our staff will be in touch. 3 Dividend Stocks with a Yield Above 5% That Are on Sale Now, Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher, Proterra Inc., A Penny Stock To Put On The Watchlist, Buffett Reduces Taiwan Semiconductor Stake After This Happened, Nio Inc - (NYSE:NIO) Shares Sold by National Bank of Canada FI, Get 30 Days of MarketBeat All Access Free, By creating a free account, you agree to our, Why Restaurant Stocks are the Stocks to Buy Right Now, View 3 Dividend Stocks with a Yield Above 5% That Are on Sale Now, View Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher, View Proterra Inc., A Penny Stock To Put On The Watchlist, View 3 Healthcare Stocks Insiders Are Buying, View Buffett Reduces Taiwan Semiconductor Stake After This Happened, View Nio Inc - (NYSE:NIO) Shares Sold by National Bank of Canada FI. TRUFORMA is the company's innovative diagnostic tool that aims to replace old-fashioned methods of diagnosis that require patient samples to be sent to an outside lab for testing before therapeutic or prescription treatments can be offered. All rights reserved. With the instrument and three of five of the initial assays available for sale, the decision was made to initiate the commercial launch of TRUFORMA ahead of the previously disclosed March 30th schedule. The device, which is on pace to launch by the end of first quarter of 2020, is expecting to earn a large share of the estimated $2.7 billion companion pet diagnostic and healthcare market expected by 2024. If you are eyeing this penny stock, prudence would dictate waiting for some confirmation that Truforma is delivering as advertised. Its not a pretty picture if youre trying to get a handle on where this companys shares are going to go next. This category only includes cookies that ensures basic functionalities and security features of the website. It is mandatory to procure user consent prior to running these cookies on your website. Offering complete thyroid testing on-site for both dogs and cats will allow our internal medicine service to provide timely answers to anxious pet owners. But opting out of some of these cookies may affect your browsing experience. This communication was produced by PCG Digital Holdings, LLC, and affiliate of PCG Advisory Inc., (together PCG). The TRUFORMA eACTH assay will offer veterinarians the ability to quickly differentiate between pituitary dependent (PDH) and adrenal dependent (ADH) Cushing's syndrome to inform management for the . We are, of course, approaching our planned March 30 th commercial launch of TRUFORMA, our point-of-care diagnostic platform. ZOM Stock Valuation: At face value, the present $2-ish ZOM stock price looks low compared to the mentioned competitors. Identify stocks that meet your criteria using seven unique stock screeners. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding the public offering. Export data to Excel for your own analysis. Amyris May be Oversold, but is it Worth Fighting the Shorts? Uh-Oh. I very much look forward to being able to report our first sale following launch.. 2023 InvestorPlace Media, LLC. Despite the drama over the past three weeks, ZOM shares are still up more than 2,500% compared to the value in late October. Its hard to come by the exact figures of how much Zomedicas competitors make in the companion animal diagnostics market. We cannot guarantee future results, performance or achievements. 100 Phoenix DriveSuite 125Ann Arbor, MI 48108, General inquiries: info@zomedica.comInvestor inquiries: investors@zomedica.com, Privacy Notice | Terms of Use | Supplier Terms & Conditions | Minimum Advertised Pricing | Customer Terms & Conditions | Forward Looking Statements. By clicking Accept All, you consent to the use of ALL the cookies. A paper from the Journal of Feline Medicine and Surgery estimated that 10% of cats over the age of 10 will develop hyperthyroidism. NYSEAMERICAN:ZOM is fast approaching what shareholders are hoping to be a defining moment in the company's history at the end of March. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Endogenous ACTH and free T4 are expected to be available during the coming weeks. We cannot guarantee future results, performance or achievements. Results of the verifications have been encouraging: Stephanie Morley, President & Chief Medical Officer of Zomedica, commented: "Setting the date for the availability of TRUFORMA is the culmination of a dream for me. Dr. Berg commented that, As a veterinary internist and business owner, I have devoted myself to advancing the practice of veterinary internal medicine and delivering care with a difference doing more, providing more, and caring more. Importantly, the lower limit of quantification for the feline assay enabled statistically significant (P value = 0.002) discrimination between normal and hyperthyroid feline serum samples. Using the BAW, Zomedicas verification studies are evaluating a total of three thyroid and adrenal assays intended for use with the TRUFORMA platform at commercial launch. Although the company has applied for four patents, a portion of any revenue will have to be paid to the owners of the intellectual property. Zomedica believes that the TRUFORMA platform represents the first use of BAW technology in disorder and disease-state diagnostics. This webinar will introduce attendees to the use of biomarkers in critical illness; more specifically the use of the endocrine parameters; cortisol and thyroxine in canine critical illness. Readers are cautioned that this list of risk factors should not be construed as exhaustive. A highly respected board-certified veterinary internist and neurologist, Dr. Bergs dedication to advancing the field of veterinary medicine has garnered national and international recognition. Dr. Cook has published numerous articles and book chapters on various aspects of small-animal medicine and regularly speaks at national veterinary meetings. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop a distribution network and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Dr. Berg commented that, As a veterinary internist and business owner, I have devoted myself to advancing the practice of veterinary internal medicine and delivering care with a difference doing more, providing more, and caring more. The companion animal business at Zoetis bought in roughly $3.65 billion in 2020 representing over 50% of the companys overall revenue. Just how big is Zomedicas addressable market. IDEXX is trading well over $500 a piece. The dynamic range of the canine TRUFORMA fT4 assay is 7.4-77.2 pmol/L compared to the Siemens IMMULITE Veterinary Free T4 assay dynamic range of 3.9-77.2 pmol/L. The combined dynamic range of the canine and feline TRUFORMA tT4 assay is 0.45-30.0 g/dL compared to the Siemens IMMULITE tT4 assay dynamic range of 0.5-15 g/dL. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop a distribution network and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. 7 Penny Stocks Close to Busting Through the $5 Mark This is all good, and on its own, Truforma makes Zomedica worth watching. A sought-after lecturer and instructor, Dr. Berg has published numerous articles in peer-reviewed journals, including those of the American VeterinaryMedical Association (AVMA), the American College of Veterinary Internal Medicine (ACVIM), and the American Animal Hospital Association (AAHA). According to Zomedica, the time to result for the TRUFORMA TSH assay is less than 20 minutes. The Major Red Flag That BBBY Stock Investors Need to Know About. And thats OK with him. The negative 5 cents per share was also a significant improvement over the negative 19 cents per share reported in 2019. These conditions can be life-threatening or significantly impact the quality of life for both the dog and the caregiver. BAW technology, also used in cell phones and in the worlds most advanced radar and communications systems, is an extremely reliable and precise technology. Thats possible thanks to the bulk acoustic wave (BAW) technology. Investor Relations Contact: PCG Advisory Kirin Smith, Presidentksmith@pcgadvisory.com+1 646.823.8656, https://www.linkedin.com/company/zomedica. Adding in the dog market and TRUFORMA has the potential to become a favored platform and tool for use in veterinary practices. 2023 Benzinga.com. Dr. Cook has published numerous articles and book chapters on various aspects of small-animal medicine and regularly speaks at national veterinary meetings. Truforma goes on sale starting March 30. The first and only feline-optimized TSH assay, which will help veterinarians more readily differentiate between hyperthyroidism and euthyroid sick syndrome. And if the company has to wait for some revenue, its best to have some cash on hand. The Major Red Flag That BBBY Stock Investors Need to Know About. Video Link: https://www.youtube.com/embed/HDDbf76Ngt4. The company describes Truforma as a biosensor platform intended for helping veterinarians in diagnosing complex conditions in cats and dogs. Six months ago, 15 million shares would trade hands on a good day. In his latest feat, Louis discovered the Master Key to profiting fromthe biggest tech revolution of this (or any) generation. This assay will enable quantification of samples with low levels of TSH, which is necessary to discriminate normal and hyperthyroid feline samples. quotes delayed at least 15 minutes, all others at least 20 minutes. Year to date, ZOM stock is up 793%. Verification data comparing the canine TRUFORMA TSH assay to the Siemens IMMULITE Canine TSH assay showed high correlation (R=0.99). View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Fill out the form below and well send along some additional materials to help you decide if TRUFORMA is a good fit for your clinic. Prepares to Launch Veterinarian Diagnostic Device, TRUFORMA(TM); Has Potential to Change Diagnostic Landscape in Animal Health (NYSE American: ZOM) PRESS RELEASE Accesswire Aug. 13 . Flexible use cases: At launch, the Truforma would support tests for adrenal and thyroid disorders in cats and dogs. Americans were already spending a fortune on pet health care ($29.3 billion in the vet office in 2019). Canine-Optimized Cortisol assay that delivers reference lab accuracy with point-of-care convenience. We dedicate ourselves to serving the needs of the broader veterinary community by offering lab services through Bloodhound laboratories, which will allow our practice partners to also advance their endocrine practice. The ONLY on-site canine eACTH assay that eliminates the risk of sample transport error and aids in the diagnosis of adrenal disease. BVSc, MMedVet(Med), PhD, DSAM, Dipl, ECVIM. 2023 Zomedica Corp. and Zomedica Inc. All rights reserved. A sought-after lecturer and instructor, Dr. Berg has published numerous articles in peer-reviewed journals, including those of the American VeterinaryMedical Association (AVMA), the American College of Veterinary Internal Medicine (ACVIM), and the American Animal Hospital Association (AAHA). Protected by approximately 70 issued and pending patents, the TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology, developed by Qorvo (NASDAQ: QRVO), to provide a non-optical and fluorescence-free detection system for use at the point-of-care. Without any revenue coming through the door, the best thing that investors can hope for is a less bad earnings report. Flexible use cases: At launch, the Truforma would support tests for adrenal and thyroid disorders in cats and dogs. PCG may be compensated by respective clients for publicizing information relating to its clients securities. We believe that this will be the first fT4 assay available at the point-of-care. Regardless- Truforma is the real deal , FDA approved & ready to launch. 5 Hypergrowth Stocks With 10X Potential in 2023, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. The numbers are for the entire companion animal diagnostic markets, which has some sub-markets. Nasdaq With chatter ramping up on Reddit, ZOM put together another big surge in February, gaining 137% over three sessions. At IDEXX, the companion animal group raked in approximately $2.39 billion in 2020 which represents 88% of the companys 2020 revenue. The launch of the TRUFORMAplatform is an exciting and disruptive milestone in the veterinary diagnostics testing industry that will raise the standard of point-of-care for companion animals.. Copyright These assays comprise testing panels for adrenal and thyroid conditions. Early Bird Registration (September 13-October 17) - $120. ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp.(NYSE American: ZOM) (Zomedica or the Company), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it expects to begin commercialization of its TRUFORMA point-of-care diagnostic platform on March 30, 2021. Its products would be competing against established names like IDEXX Laboratories (NASDAQ:IDXX) and Zoetis (NYSE:ZTS). Total-T4 Assay with enhanced dynamic range. quotes delayed at least 15 minutes, all others at least 20 minutes. However, ZOM does not own the technology underlying Truforma and according to. Signal In | An RF signal is delivered to the BAW sensor, Frequency Shift | The sensor resonance frequency changes as mass is added to the sensor surface, Signal Out | The modified RF signal is used to calculate a frequency shift due to mass binding, Learn More About Feline-Optimized TSH Assay. Verification data comparing the canine and feline TRUFORMA tT4 assay to the Siemens IMMULITE Canine tT4 reference lab assay showed high correlation (R=0.94). His office currently waits 2 days for cortisol test results, 48 hours. Zomedica partnered with semiconductor company Qorvo (NASDAQ:QRVO) to bring this tech to the point-of-care veterinary practice for the first time. This website uses cookies to improve your experience while you navigate through the website. The combined dynamic range of the canine and feline TRUFORMA TSH assay is 0.008-10.0 ng/mL compared to the Siemens IMMULITE Canine TSH assay dynamic range of 0.03-12 ng/mL. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures, Media ContactCompany Name: PCG Digital HoldingsContact Person: Kenny EllisEmail: Send EmailCity: New YorkState: New YorkCountry: United StatesWebsite: https://pcgadvisory.com/, Press Release Distributed by ABNewswire.com At this stage, tests are available for thyroid and adrenal issues, but more are coming, including tests for gastrointestinal conditions currently the most common insurance claim for dog owners.

Legendary White Bison Clues Not Showing Up, Kuru Toga Advance Disassembly, Articles W